Cp h058

This study used normal endometrial cells (NECs), KLE cells, RL952 cells, Ishikawa cells, and ECC-1 cells. They were maintained and cultured as previously described [15 (link)]. The cell lines used in this study were as follows: normal endometrial cells (NEC, CP-H058, Procell, Wuhan, China), KLE (CL-0133, Procell, Wuhan, China), RL952 (CL-0197, Procell, Wuhan, China), Ishikawa (CL-0283, Procell, Wuhan, China), and ECC-1 (BS-C163325, BinSuiBio, Shanghai, China).
The following antibodies were used: Anti-METTL5 (16791-1-AP, Proteintech, Rosemont, USA), anti-Ki-67 (ab15580, Abcam, Cambridge, USA), anti-CEA (ab207718, Abcam, Cambridge, USA), anti-CA199 (ab3982, Abcam, Cambridge, USA), anti-CA153 (ab109185, Abcam, Cambridge, USA), anti-HE4 (13, ab200828, Abcam, Cambridge, USA), anti-MLH1 (ab92312, Abcam, Cambridge, USA), anti-MSH2 (ab212188, Abcam, Cambridge, USA), anti-MSH6 (ab92471, Abcam, Cambridge, USA), anti-PMS2 (ab110638, Abcam, Cambridge, USA), and anti-β-actin (M01263-2, Boster, Wuhan, China).

Normal endometrial cell lines (EMCs) (CP-H058) and the matching medium (CM-H058) were purchased from Procell Life Science & Technology Co., Ltd. (Wuhan, China). EC cells HEC-1B (HTB-113), HEC-1A (CRL-2692), AN3CA (HTB-111), and RL95-2 (CRL-1671), as well as cell culture medium and supplement including DMEM: F-12 medium (30-2006) and fetal bovine serum (FBS) (30-2020), were provided by American Type Culture Collection (ATCC, USA). Cells were cultivated in an incubator (51033546; Thermo Fisher Scientific, USA) at 37°C with 5% CO₂ under a humidified atmosphere.

Normal endometrial (NECs; CP-H058), KLE (CL-0133), RL952 (CL-0197), and Ishikawa (CL-0283) cells (all from Procell, Wuhan, China) and ECC-1 cells (BS-C163325, BinSuiBio, Shanghai, China) were maintained and cultured as previously described (16 (link)).